Sugi Predict

Sugi Predict / Targets / MALT1

MALT1

Mucosa-associated lymphoid tissue lymphoma translocation protein 1 · Q9UDY8 · MALT1 on Sugi Atlas →

44,824 patent compounds predicted against MALT1, 18,820 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL117654 SCHEMBL117654 0.52 14/20
SCHEMBL121275 SCHEMBL121275 0.34 14/20
SCHEMBL1148344 SCHEMBL1148344 0.44 13/20
SCHEMBL1148395 SCHEMBL1148395 0.43 13/20
SCHEMBL929326 SCHEMBL929326 0.35 13/20
SCHEMBL121150 SCHEMBL121150 0.33 13/20
Zoniporide Zoniporide (SCHEMBL611159) 0.42 11/20
SCHEMBL535499 SCHEMBL535499 0.34 11/20
SCHEMBL123506 SCHEMBL123506 0.33 11/20
SCHEMBL120823 SCHEMBL120823 0.32 11/20
SCHEMBL1533581 SCHEMBL1533581 0.38 10/20
SCHEMBL120729 SCHEMBL120729 0.35 10/20
SCHEMBL1533122 SCHEMBL1533122 0.33 10/20
SCHEMBL535497 SCHEMBL535497 0.33 10/20
Lapachone Lapachone (SCHEMBL107042) 1.00 9/20
Alpha-Lapachone Alpha-Lapachone (SCHEMBL102553) 0.79 9/20
Nor-Beta-Lapachone Nor-Beta-Lapachone (SCHEMBL107599) 0.71 9/20
SCHEMBL612448 SCHEMBL612448 0.64 9/20
SCHEMBL239605 SCHEMBL239605 0.61 9/20
SCHEMBL633558 SCHEMBL633558 0.58 9/20

Clinical trials — most relevant to MALT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection PHASE4COMPLETED
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma PHASE3COMPLETED
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma PHASE3COMPLETED
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type PHASE2UNKNOWN
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders PHASE1/PHASE2RECRUITING
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma PHASE1/PHASE2COMPLETED
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas PHASE2RECRUITING
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment PHASE2COMPLETED
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients PHASE2COMPLETED
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma PHASE2COMPLETED
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas PHASE2COMPLETED
Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma PHASE2COMPLETED
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma PHASE2UNKNOWN
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma PHASE2RECRUITING
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma PHASE1/PHASE2COMPLETED
Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma PHASE2UNKNOWN
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma PHASE1/PHASE2COMPLETED
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma PHASE2NOT_YET_RECRUITING
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA PHASE1RECRUITING
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL PHASE1COMPLETED
Molecular and Cellular Characterization of MALT Lymphoma nanNOT_YET_RECRUITING
Endomicroscopy and Gastric MALT-lymphoma nanCOMPLETED
Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome nanCOMPLETED
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911 nanCOMPLETED
Helicobacter Pylori and it's Hematological Impact nanCOMPLETED
TLR 9 (rs352140) Gene Polymorphism in Helicobacter Pylori Infection nanCOMPLETED
European Registry on the Management of Helicobacter Pylori Infection nanRECRUITING
Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MALT1 binder may also engage these)

ProteinNameSimilarity
Q2TBA3 — 1.000 Q2TBA3 →
Q8NFZ0 — 0.977 Q8NFZ0 →
Q9ESL4 — 0.977 Q9ESL4 →
Q69ZK0 — 0.976 Q69ZK0 →
O15519 — 0.975 O15519 →
MAP3K20 Mitogen-activated protein kinase kinase kinase 20 0.975 landscape →
Q3LAC4 — 0.975 Q3LAC4 →
Q9Z1S3 — 0.972 Q9Z1S3 →
Q6NYU2 — 0.972 Q6NYU2 →
Q8TCU6 — 0.972 Q8TCU6 →
Q5RED8 — 0.971 Q5RED8 →
HLCS Biotin--protein ligase 0.970 landscape →
P48553 — 0.970 P48553 →
O94955 — 0.970 O94955 →
Q8K2I9 — 0.970 Q8K2I9 →
Q66H91 — 0.970 Q66H91 →
Q9CTN4 — 0.969 Q9CTN4 →
Q6GR37 — 0.969 Q6GR37 →
E1C3P4 — 0.969 E1C3P4 →
Q5ZLS2 — 0.969 Q5ZLS2 →
Q9UK99 — 0.969 Q9UK99 →
Q5R7L2 — 0.969 Q5R7L2 →
Q5RD56 — 0.969 Q5RD56 →
Q3UGM2 — 0.968 Q3UGM2 →
P38438 — 0.968 P38438 →
PARP4 Protein mono-ADP-ribosyltransferase PARP4 0.968 landscape →
Q6DFV5 — 0.968 Q6DFV5 →
Q9JLQ2 — 0.967 Q9JLQ2 →
RASGRP1 RAS guanyl-releasing protein 1 0.967 landscape →
Q9CWU0 — 0.967 Q9CWU0 →